Avelumab mediates antibody-dependent cellular cytotoxicity against monocyte-derived dendritic cells through natural killer cells

Tatjana Sauerer; Franziska Bremm; Amke C. Beenen; Lukas Heger; Diana Dudziak; Naomi C. Bosch; Michael Erdmann; Carola Berking; Niels Schaft; Jan Dörrie

doi:10.1002/mco2.70111

MedComm ›› 2025, Vol. 6 ›› Issue (3) : e70111 DOI: 10.1002/mco2.70111

LETTER

Avelumab mediates antibody-dependent cellular cytotoxicity against monocyte-derived dendritic cells through natural killer cells

Author information +

History +

PDF

Cite this article

Download citation ▾

Tatjana Sauerer, Franziska Bremm, Amke C. Beenen, Lukas Heger, Diana Dudziak, Naomi C. Bosch, Michael Erdmann, Carola Berking, Niels Schaft, Jan Dörrie. Avelumab mediates antibody-dependent cellular cytotoxicity against monocyte-derived dendritic cells through natural killer cells. MedComm, 2025, 6(3): e70111 DOI:10.1002/mco2.70111

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Borgeaud M, Sandoval J, Obeid M, et al. Novel targets for immune-checkpoint inhibition in cancer. Cancer Treat Rev. 2023; 120: 102614.

[2]	Beenen AC, Sauerer T, Schaft N, Dörrie J. Beyond cancer: regulation and function of PD-L1 in health and immune-related diseases. Int J Mol Sci. 2022; 23(15): 8599.

[3]	Borges F, Laureano RS, Vanmeerbeek I, et al. Trial watch: anticancer vaccination with dendritic cells. Oncoimmunology. 2024; 13(1): 2412876.

[4]	Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody Avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015; 3(10): 1148-1157.

[5]	Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. 2018; 154(1): 3-20.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.